N(4)-oleylcytosine arabinoside

Known as: NOAC 
 
National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2016
Highly Cited
2016
In 2013, the European Heart Rhythm Association (EHRA) published a Practical Guide on the use of non-VKA oral anticoagulants… (More)
  • table 1
  • table 2
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2016
Highly Cited
2016
BACKGROUND In comparison to warfarin, non-vitamin K antagonist oral anticoagulants (NOACs) have the advantages of ease of dosing… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?
Highly Cited
2015
Highly Cited
2015
The current manuscript is an update of the original Practical Guide, published in June 2013[Heidbuchel H, Verhamme P, Alings M… (More)
  • table 1
  • table 2
  • figure 1
  • figure 2
  • table 3
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND There is a perception among physicians that lack of routine monitoring with non-vitamin K antagonist oral… (More)
Is this relevant?
Highly Cited
2015
Highly Cited
2015
BACKGROUND The Global Registry on Long-Term Oral Antithrombotic Treatment in Patients with Atrial Fibrillation (GLORIA-AF) was… (More)
Is this relevant?
Highly Cited
2014
Highly Cited
2014
Worldwide, rivaroxaban is increasingly used for stroke prevention in atrial fibrillation and treatment of venous thromboembolism… (More)
  • table 1
  • table 2
  • figure 1
  • table 3
Is this relevant?
Highly Cited
2014
Highly Cited
2014
AIMS Patients receiving novel oral anticoagulants (NOACs) frequently undergo interventional procedures. Short half-lives and… (More)
  • table 3
  • table 4
  • table 5
  • table 6
Is this relevant?
Highly Cited
2013
Highly Cited
2013
New oral anticoagulants (NOACs) are an alternative for vitamin K antagonists (VKAs) to prevent stroke in patients with non… (More)
  • table 1
  • figure 1
  • figure 2
  • table 2
  • table 3
Is this relevant?
Highly Cited
2013
Highly Cited
2013
Direct new oral anticoagulants (NOACs) - inhibitors of thrombin or factor Xa - are intended to be used largely in the treatment… (More)
Is this relevant?
2012
2012
OBJECTIVE The randomized clinical trials, RE-LY, ROCKET-AF, and ARISTOTLE, demonstrate that the novel oral anticoagulants (NOACs… (More)
  • table 1
  • table 2
  • table 3
  • table 4
  • figure 1
Is this relevant?